FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
Abstract Purpose Glioma is the most common primary intracranial tumor. Owing to the poor prognosis associated with high-grade gliomas, there is an urgent need to identify biomarkers related to prognosis and treatment sensitivity. Here, we analyze the expression of FXYD2 mRNA in gliomas, and explore...
Guardado en:
Autores principales: | Kaijia Zhou, Tao Jiang, Yanwei Liu, Zheng Zhao, Lijie Huang, Guanzhang Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec583aa011414843a3d061c175e3fe74 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Size-dependent chemosensitization of doxorubicin-loaded polymeric nanoparticles for malignant glioma chemotherapy
por: Meng Gao, et al.
Publicado: (2021) -
Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Fabiana Gregucci, et al.
Publicado: (2021) -
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
por: Shi H, et al.
Publicado: (2020) -
New Autophagy-Ferroptosis Gene Signature Predicts Survival in Glioma
por: Liwei Zhou, et al.
Publicado: (2021) -
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment
por: Peng Y, et al.
Publicado: (2018)